
Research peptides
SS-31
Also known as Elamipretide
SS-31 (elamipretide; also MTP-131) is a synthetic Szeto-Schiller tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2, that targets the inner mitochondrial membrane. As elamipretide hydrochloride (FORZINITY), it received FDA accelerated approval in September 2025 for one rare-disease indication.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 10 mg, lot SS31-10-0803: 99.77% purity (RP-HPLC), 10.44 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7584
- 30 mg, lot SS31-30-0803: 99.78% purity (RP-HPLC), 30.84 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7579
- 50 mg, lot SS31-50-0803: 99.75% purity (RP-HPLC), 50.90 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7590
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Barth syndrome muscle strength
- Primary mitochondrial myopathy
- Heart failure with reduced ejection fraction
- Age-related macular degeneration
- Cardiolipin and mitochondrial bioenergetics
How it is thought to work
SS-31 binds cardiolipin, a phospholipid found in the inner mitochondrial membrane, through electrostatic and hydrophobic interactions. In laboratory studies this interaction limits cardiolipin's conversion of cytochrome c into a peroxidase while preserving its electron-carrying role, and is associated with preserved cristae structure and oxidative phosphorylation. The FDA label describes it as a mitochondrial cardiolipin binder.
Where the research stands
FDA accelerated approval (Barth syndrome). FORZINITY (NDA 215244) was approved on September 19, 2025 to improve muscle strength in Barth syndrome patients weighing at least 30 kg, based on an intermediate endpoint, with continued approval contingent on confirmatory trials; other uses remain investigational.
Sources
- Stealth BioTherapeutics Inc. (2025). FORZINITY (elamipretide hydrochloride) injection - prescribing information. DailyMed (U.S. National Library of Medicine).
- U.S. Food and Drug Administration (2025). Drugs@FDA: FORZINITY, NDA 215244. Drugs@FDA.
- Szeto HH (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.. British Journal of Pharmacology.
- Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. Genetics in Medicine.
Read more
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.
